Ho et al. (2023) reported heterogeneous BAFF signaling and B-cell reconstitution patterns following anti-CD20 therapy, suggesting that individual variability in BAFF pathways may impact treatment outcomes and immune risk profiles [27]. Conversely, Gupta et al. (2023)provided evidence that elevated BAFF levels post-B-cell depletion might support regulatory B-cell populations and help limit CNS autoimmunity, cautioning against indiscriminate BAFF suppression [28]. Here, TNFSF13B is linked to Autoimmunity.